BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Prostate cancer AND NR4A3, MINOR, 8013, ENSG00000119508, Q92570, CHN, NOR1, CSMF AND Clinical Outcome
8 results:

  • 1. Synthesis and evaluation of 7-(3-aminopropyloxy)-substituted flavone analogue as a topoisomerase IIα catalytic inhibitor and its sensitizing effect to enzalutamide in castration-resistant prostate cancer cells.
    Jeon KH; Park S; Shin JH; Jung AR; Hwang SY; Seo SH; Jo H; Na Y; Kwon Y
    Eur J Med Chem; 2023 Jan; 246():114999. PubMed ID: 36493620
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Association of genetic variation of the six gene prognostic model for castration-resistant prostate cancer with survival.
    Xie W; Stopsack KH; Drouin SJ; Fu H; Pomerantz MM; Mucci LA; Lee GM; Kantoff PW
    Prostate; 2019 Jan; 79(1):73-80. PubMed ID: 30141208
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel.
    Wissing MD; Coenen JL; van den Berg P; Westgeest HM; van den Eertwegh AJ; van Oort IM; Bos MM; Bergman AM; Hamberg P; Ten Tije AJ; Los M; Lolkema MP; de Wit R; Gelderblom H
    Int J Cancer; 2015 Mar; 136(6):E760-72. PubMed ID: 25242736
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. GreenLight™ laser in the treatment of lower urinary tract symptoms due to benign prostatic enlargement.
    Antoniewicz AA; Alivizatos G; Zapała Ł; de Reijke TM
    Expert Rev Med Devices; 2011 Mar; 8(2):139-47. PubMed ID: 21381906
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Long-term clinical outcome of diagnostic transurethral resection of the prostate in patients with elevated prostate-specific antigen level and minor lower urinary tract symptoms.
    van Renterghem K; van Koeveringe G; Achten R; van Kerrebroeck P
    Urol Int; 2009; 83(1):60-5. PubMed ID: 19641361
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Positive surgical margins after radical prostatectomy: do they have an impact on biochemical or clinical progression?
    Pfitzenmaier J; Pahernik S; Tremmel T; Haferkamp A; Buse S; Hohenfellner M
    BJU Int; 2008 Nov; 102(10):1413-8. PubMed ID: 18537951
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. prostate cryoablation using direct transperineal placement of ultrathin probes through a 17-gauge brachytherapy template-technique and preliminary results.
    Zisman A; Pantuck AJ; Cohen JK; Belldegrun AS
    Urology; 2001 Dec; 58(6):988-93. PubMed ID: 11744474
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Economic and organizational aspects in the management of prostate cancer.
    Cellini N; Luzi S; Morganti AG; Mattiucci GC; Smaniotto D; Racioppi M
    Rays; 1999; 24(3):460-71. PubMed ID: 10605307
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.